# HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer

> **NCT01984359** · NA · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 80 (actual)

## Conditions studied

- Subjects With p16 Positive/HPV Positive Squamous Cell Carcinomas of the Oropharynx

## Interventions

- **OTHER:** Obtaining Human tissue

## Key facts

- **NCT ID:** NCT01984359
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-12
- **Final completion:** 2018-05-24
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2020-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01984359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01984359, "HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01984359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*